AstraZeneca raises profit outlook on strong medicines demand
Expects 2024 sales and profit to grow by a mid teens percentage
Q2 sales of $12.94 billion beat forecast, core EPS $1.98 in line
Shares fell as much as 4%
Updates shares in paragraph 4
By Pushkala Aripaka and Maggie Fick
July 25 (Reuters) -Anglo-Swedish drugmaker AstraZeneca AZN.L raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong demand for its cancer, rare disease and heart disease medicines.
Sales in AstraZeneca's top business, oncology, grew 19% at constant currency rates to $5.33 billion and accounted for 41% of the total, while its rare disease and heart and kidney disease divisions also each raked in double-digit growth.
Second-quarter profit though was dented by a rise in expenses and sales of cancer drugs Enhertu and Imfinzi were slightly softer than expected, analysts said.
The shares slipped by as much as 4%. They were down 2.4% at 1000GMT after gains of about 14% so far this year. But on Thursday they wereone of the worst performers in the European pharma sector, which was down 0.14% .SXDP.
British rival GSK's GSK.L shares are up 4.1% this year and Swiss drugmaker Roche ROG.S is up 11% this year, compared with the STOXX 600 Index gains of 7%.
AstraZeneca expects both 2024 revenue and core earnings per share to increase by a mid-teens percentage at constant currency rates, it said. It had previously expected revenue and profit to increase by a low double-digit to low-teens percentage.
The UK's most valuable company in terms of its market capitalisation of 189.4 billion pounds ($243.89 billion) has evolved significantly since CEO Pascal Soriot took over 12 years ago. New technologies such as antibody-drug conjugates are making up a rising proportion of its future cancer therapies.
The sales outlook reflects how the company has moved beyond the COVID vaccine, its best-selling product at the height of the pandemic in 2021, thanks to its roster of cancer therapies and a strong pipeline, including new treatments in other disease areas by the end of the decade.
"In the year to date we have continued to make encouraging progress with several disruptive technologies ... all of which have the potential to drive our growth beyond 2030," CEO Soriot said in a statement.
At its investor day in May, the company announced it aimed to grow revenue by about 75% to $80 billion by 2030, citing the expected launch of 20 new medicines and growth in its cancer, biopharmaceuticals and rare disease portfolio.
The company has been investing in building its pipeline and marketing new launches. In May, AstraZeneca said that a plant in Qingdao, China, will help it build a distinct local supply chain to serve the Chinese market, its second largest globally.
Operating expenses in the quarter were 14% higher at $6.74 billion.
Total revenue rose 17% on a constant-currency basis to $12.94 billion for the three months ended June, while core earnings came in at $1.98 per share, compared with analysts' average expectation of $12.6 billion and $1.98 per share, respectively, according to a company-compiled consensus.
AstraZeneca increased its interim dividend by 7 cents to $1.
($1 = 0.7766 pounds)
Reporting by Pushkala Aripaka in Bengaluru and Maggie Fick in London; Editing by Sonia Cheema and Elaine Hardcastle
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
